SOPHiA GENETICS S.A. (NASDAQ: SOPH) Stock Competitors & Peer Comparison

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, VEEV has a market cap of 31.7B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while VEEV trades at $195.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas VEEV's P/E ratio is 23.46. In terms of profitability, SOPH's ROE is -1.41%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, SOPH is more volatile compared to VEEV. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check VEEV's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, GEHC has a market cap of 28.7B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while GEHC trades at $63.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas GEHC's P/E ratio is 13.83. In terms of profitability, SOPH's ROE is -1.41%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, SOPH is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check GEHC's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas GEHCV's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, SOPH is more volatile compared to GEHCV. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check GEHCV's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, BTSG has a market cap of 13.9B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while BTSG trades at $70.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas BTSG's P/E ratio is 57.01. In terms of profitability, SOPH's ROE is -1.41%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, SOPH is more volatile compared to BTSG. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check BTSG's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, BTSGU has a market cap of 13.5B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while BTSGU trades at $231.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas BTSGU's P/E ratio is 209.36. In terms of profitability, SOPH's ROE is -1.41%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, SOPH is more volatile compared to BTSGU. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check BTSGU's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, TEM has a market cap of 9.2B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while TEM trades at $52.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas TEM's P/E ratio is -104.94. In terms of profitability, SOPH's ROE is -1.41%, compared to TEM's ROE of -0.70%. Regarding short-term risk, SOPH is more volatile compared to TEM. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check TEM's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SGFY's P/E ratio is 70.91. In terms of profitability, SOPH's ROE is -1.41%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, SOPH is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check SGFY's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, HQY has a market cap of 8.3B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while HQY trades at $97.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas HQY's P/E ratio is 23.06. In terms of profitability, SOPH's ROE is -1.41%, compared to HQY's ROE of +0.11%. Regarding short-term risk, SOPH is more volatile compared to HQY. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check HQY's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, HNGE has a market cap of 6.7B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while HNGE trades at $87.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas HNGE's P/E ratio is 44.66. In terms of profitability, SOPH's ROE is -1.41%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, SOPH is more volatile compared to HNGE. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check HNGE's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas RCM's P/E ratio is -102.21. In terms of profitability, SOPH's ROE is -1.41%, compared to RCM's ROE of +0.00%. Regarding short-term risk, SOPH is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check RCM's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, TXG has a market cap of 5.6B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while TXG trades at $43.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas TXG's P/E ratio is -257.29. In terms of profitability, SOPH's ROE is -1.41%, compared to TXG's ROE of -0.03%. Regarding short-term risk, SOPH is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check TXG's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, DOCS has a market cap of 4B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while DOCS trades at $21.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas DOCS's P/E ratio is 14.07. In terms of profitability, SOPH's ROE is -1.41%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, SOPH is more volatile compared to DOCS. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check DOCS's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas ONEM's P/E ratio is -7.77. In terms of profitability, SOPH's ROE is -1.41%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, SOPH is more volatile compared to ONEM. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check ONEM's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, PRVA has a market cap of 3.4B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while PRVA trades at $26.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas PRVA's P/E ratio is 168.13. In terms of profitability, SOPH's ROE is -1.41%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to PRVA. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check PRVA's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, PGNY has a market cap of 2.5B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while PGNY trades at $31.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas PGNY's P/E ratio is 23.31. In terms of profitability, SOPH's ROE is -1.41%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, SOPH is more volatile compared to PGNY. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check PGNY's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, HTFL has a market cap of 2.2B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while HTFL trades at $24.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas HTFL's P/E ratio is -12.92. In terms of profitability, SOPH's ROE is -1.41%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, SOPH is more volatile compared to HTFL. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check HTFL's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while WGS trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas WGS's P/E ratio is 74.68. In terms of profitability, SOPH's ROE is -1.41%, compared to WGS's ROE of -0.28%. Regarding short-term risk, SOPH is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check WGS's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, TDOC has a market cap of 1.7B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while TDOC trades at $9.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas TDOC's P/E ratio is -10.47. In terms of profitability, SOPH's ROE is -1.41%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, SOPH is more volatile compared to TDOC. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check TDOC's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas NXGN's P/E ratio is -266.00. In terms of profitability, SOPH's ROE is -1.41%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, SOPH is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check NXGN's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, OMDA has a market cap of 1.4B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while OMDA trades at $23.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas OMDA's P/E ratio is 338.57. In terms of profitability, SOPH's ROE is -1.41%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, SOPH is more volatile compared to OMDA. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check OMDA's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas AGTI's P/E ratio is -71.79. In terms of profitability, SOPH's ROE is -1.41%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, SOPH is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check AGTI's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, GDRX has a market cap of 1.1B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while GDRX trades at $3.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas GDRX's P/E ratio is 9.52. In terms of profitability, SOPH's ROE is -1.41%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to GDRX. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check GDRX's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CERT has a market cap of 1.1B. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CERT trades at $6.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CERT's P/E ratio is 17.77. In terms of profitability, SOPH's ROE is -1.41%, compared to CERT's ROE of -0.01%. Regarding short-term risk, SOPH is more volatile compared to CERT. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CERT's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CCLDO's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, SOPH is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CCLDO's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, HSTM has a market cap of 845.5M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while HSTM trades at $28.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas HSTM's P/E ratio is 38.08. In terms of profitability, SOPH's ROE is -1.41%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, SOPH is more volatile compared to HSTM. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check HSTM's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, WGSWW has a market cap of 748M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while WGSWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas WGSWW's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -1.41%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, SOPH is less volatile compared to WGSWW. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check WGSWW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, PHR has a market cap of 662M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while PHR trades at $10.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas PHR's P/E ratio is 38.25. In terms of profitability, SOPH's ROE is -1.41%, compared to PHR's ROE of +0.03%. Regarding short-term risk, SOPH is more volatile compared to PHR. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check PHR's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, EVH has a market cap of 652.4M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while EVH trades at $5.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas EVH's P/E ratio is 580.00. In terms of profitability, SOPH's ROE is -1.41%, compared to EVH's ROE of -0.78%. Regarding short-term risk, SOPH is more volatile compared to EVH. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check EVH's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, SOPH is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check MPLN-WT's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas ACCD's P/E ratio is -3.08. In terms of profitability, SOPH's ROE is -1.41%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, SOPH is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check ACCD's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SHCR's P/E ratio is -3.76. In terms of profitability, SOPH's ROE is -1.41%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, SOPH is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check SHCR's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CTEV has a market cap of 517.5M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CTEV trades at $30.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CTEV's P/E ratio is -2.33. In terms of profitability, SOPH's ROE is -1.41%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, SOPH is more volatile compared to CTEV. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CTEV's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, NRC has a market cap of 490.8M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while NRC trades at $21.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas NRC's P/E ratio is 26.56. In terms of profitability, SOPH's ROE is -1.41%, compared to NRC's ROE of +0.57%. Regarding short-term risk, SOPH is more volatile compared to NRC. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check NRC's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SLGC's P/E ratio is -3.04. In terms of profitability, SOPH's ROE is -1.41%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, SOPH is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check SLGC's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, SOPH's ROE is -1.41%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, SOPH is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check SLGCW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while TBRG trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas TBRG's P/E ratio is 9.37. In terms of profitability, SOPH's ROE is -1.41%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, SOPH is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check TBRG's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas MPLN's P/E ratio is -0.23. In terms of profitability, SOPH's ROE is -1.41%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, SOPH is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check MPLN's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SLP has a market cap of 368.7M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SLP trades at $18.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SLP's P/E ratio is 20.72. In terms of profitability, SOPH's ROE is -1.41%, compared to SLP's ROE of +0.06%. Regarding short-term risk, SOPH is more volatile compared to SLP. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check SLP's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas TRHC's P/E ratio is -4.27. In terms of profitability, SOPH's ROE is -1.41%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, SOPH is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check TRHC's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SMFR's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, SOPH is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check SMFR's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SPOK has a market cap of 222.2M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SPOK trades at $10.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SPOK's P/E ratio is 17.73. In terms of profitability, SOPH's ROE is -1.41%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, SOPH is more volatile compared to SPOK. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check SPOK's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SY has a market cap of 220.4M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SY trades at $1.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SY's P/E ratio is -5.09. In terms of profitability, SOPH's ROE is -1.41%, compared to SY's ROE of -0.16%. Regarding short-term risk, SOPH is more volatile compared to SY. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check SY's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, AMWL has a market cap of 220.3M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while AMWL trades at $13.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas AMWL's P/E ratio is -2.54. In terms of profitability, SOPH's ROE is -1.41%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, SOPH is less volatile compared to AMWL. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check AMWL's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, HCAT has a market cap of 166.3M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while HCAT trades at $2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas HCAT's P/E ratio is 11.25. In terms of profitability, SOPH's ROE is -1.41%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, SOPH is more volatile compared to HCAT. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check HCAT's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CPSI's P/E ratio is -183.80. In terms of profitability, SOPH's ROE is -1.41%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, SOPH is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check CPSI's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, OPRX has a market cap of 125.5M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while OPRX trades at $6.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas OPRX's P/E ratio is 6.14. In terms of profitability, SOPH's ROE is -1.41%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, SOPH is more volatile compared to OPRX. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check OPRX's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas AUGX's P/E ratio is -4.99. In terms of profitability, SOPH's ROE is -1.41%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, SOPH is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check AUGX's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CCLD has a market cap of 98.6M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CCLD trades at $2.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CCLD's P/E ratio is 8.59. In terms of profitability, SOPH's ROE is -1.41%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, SOPH is more volatile compared to CCLD. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CCLD's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, DH has a market cap of 80.1M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while DH trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas DH's P/E ratio is 2.92. In terms of profitability, SOPH's ROE is -1.41%, compared to DH's ROE of -0.67%. Regarding short-term risk, SOPH is more volatile compared to DH. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check DH's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas FORA's P/E ratio is -24.11. In terms of profitability, SOPH's ROE is -1.41%, compared to FORA's ROE of -0.17%. Regarding short-term risk, SOPH is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check FORA's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CCLDP's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, SOPH is more volatile compared to CCLDP. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CCLDP's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, ONMD has a market cap of 38.7M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while ONMD trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas ONMD's P/E ratio is -4.53. In terms of profitability, SOPH's ROE is -1.41%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, SOPH is more volatile compared to ONMD. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check ONMD's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SNCE's P/E ratio is -0.27. In terms of profitability, SOPH's ROE is -1.41%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, SOPH is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check SNCE's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas AKLI's P/E ratio is -0.71. In terms of profitability, SOPH's ROE is -1.41%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, SOPH is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check AKLI's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SHLT's P/E ratio is -3.87. In terms of profitability, SOPH's ROE is -1.41%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, SOPH is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check SHLT's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -1.41%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, SOPH is more volatile compared to SHCRW. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check SHCRW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, ONMDW has a market cap of 27.7M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while ONMDW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas ONMDW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, SOPH is more volatile compared to ONMDW. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check ONMDW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas STRM's P/E ratio is -2.40. In terms of profitability, SOPH's ROE is -1.41%, compared to STRM's ROE of -0.32%. Regarding short-term risk, SOPH is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check STRM's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas RNLX's P/E ratio is -0.33. In terms of profitability, SOPH's ROE is -1.41%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, SOPH is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check RNLX's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas LIFW's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -1.41%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, SOPH is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check LIFW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, EUDA has a market cap of 21.1M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while EUDA trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas EUDA's P/E ratio is -21.32. In terms of profitability, SOPH's ROE is -1.41%, compared to EUDA's ROE of +0.70%. Regarding short-term risk, SOPH is more volatile compared to EUDA. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check EUDA's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas BBLN's P/E ratio is -0.04. In terms of profitability, SOPH's ROE is -1.41%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, SOPH is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check BBLN's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, BEATW has a market cap of 13.4M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while BEATW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas BEATW's P/E ratio is -0.04. In terms of profitability, SOPH's ROE is -1.41%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, SOPH is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check BEATW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas ETAO's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -1.41%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, SOPH is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check ETAO's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, BFRG has a market cap of 7.5M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while BFRG trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas BFRG's P/E ratio is -1.20. In terms of profitability, SOPH's ROE is -1.41%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, SOPH is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check BFRG's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas HLTH's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -1.41%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, SOPH is less volatile compared to HLTH. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check HLTH's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, SCNX has a market cap of 6.4M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while SCNX trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas SCNX's P/E ratio is -0.16. In terms of profitability, SOPH's ROE is -1.41%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, SOPH is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check SCNX's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas UPH's P/E ratio is -0.07. In terms of profitability, SOPH's ROE is -1.41%, compared to UPH's ROE of -1.05%. Regarding short-term risk, SOPH is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check UPH's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, SOPH is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check UPH-WT's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, MGRX has a market cap of 4.2M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while MGRX trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas MGRX's P/E ratio is -0.31. In terms of profitability, SOPH's ROE is -1.41%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, SOPH is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check MGRX's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas PEAR's P/E ratio is -0.08. In terms of profitability, SOPH's ROE is -1.41%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, SOPH is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check PEAR's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas PEARW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -1.41%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, SOPH is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check PEARW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas OTRK's P/E ratio is -0.02. In terms of profitability, SOPH's ROE is -1.41%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, SOPH is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check OTRK's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, VSEEW has a market cap of 2.2M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while VSEEW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas VSEEW's P/E ratio is -0.06. In terms of profitability, SOPH's ROE is -1.41%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, SOPH is more volatile compared to VSEEW. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check VSEEW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, HCTI has a market cap of 2.1M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while HCTI trades at $1.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas HCTI's P/E ratio is -0.23. In terms of profitability, SOPH's ROE is -1.41%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, SOPH is more volatile compared to HCTI. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check HCTI's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CMAX's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -1.41%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, SOPH is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CMAX's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, VSEE has a market cap of 1.6M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while VSEE trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas VSEE's P/E ratio is -0.19. In terms of profitability, SOPH's ROE is -1.41%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, SOPH is more volatile compared to VSEE. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check VSEE's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, ACON has a market cap of 1.3M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while ACON trades at $2.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas ACON's P/E ratio is -0.24. In terms of profitability, SOPH's ROE is -1.41%, compared to ACON's ROE of -0.54%. Regarding short-term risk, SOPH is more volatile compared to ACON. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check ACON's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, SOPH is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check LIFWZ's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, EUDAW has a market cap of 926.3K. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while EUDAW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, SOPH's ROE is -1.41%, compared to EUDAW's ROE of +0.70%. Regarding short-term risk, SOPH is less volatile compared to EUDAW. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check EUDAW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, WORX has a market cap of 693.4K. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while WORX trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas WORX's P/E ratio is -0.76. In terms of profitability, SOPH's ROE is -1.41%, compared to WORX's ROE of -0.65%. Regarding short-term risk, SOPH is more volatile compared to WORX. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check WORX's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, SOPH is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check MSPRZ's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas KERN's P/E ratio is -0.01. In terms of profitability, SOPH's ROE is -1.41%, compared to KERN's ROE of -0.17%. Regarding short-term risk, SOPH is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check KERN's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas KERNW's P/E ratio is -0.00. In terms of profitability, SOPH's ROE is -1.41%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, SOPH is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check KERNW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas LIFWW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, SOPH is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check LIFWW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, ZCMD has a market cap of 58K. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while ZCMD trades at $1.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas ZCMD's P/E ratio is -0.06. In terms of profitability, SOPH's ROE is -1.41%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, SOPH is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check ZCMD's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CMAXW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, SOPH is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CMAXW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, ACONW has a market cap of 11.7K. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while ACONW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas ACONW's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, SOPH is more volatile compared to ACONW. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check ACONW's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas MTBCO's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, SOPH is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check MTBCO's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas MSPRV's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to MSPRV's ROE of N/A. Regarding short-term risk, SOPH is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check MSPRV's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas MTBCP's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, SOPH is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check MTBCP's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas MTBC's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, SOPH is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check MTBC's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CHNG's P/E ratio is -152.72. In terms of profitability, SOPH's ROE is -1.41%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, SOPH is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CHNG's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CHNGU's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, SOPH is more volatile compared to CHNGU. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CHNGU's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CNVY's P/E ratio is -71.50. In terms of profitability, SOPH's ROE is -1.41%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, SOPH is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CNVY's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while NAVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas NAVA's P/E ratio is N/A. In terms of profitability, SOPH's ROE is -1.41%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, SOPH is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for SOPH.Check NAVA's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CERN has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CERN's P/E ratio is 55.84. In terms of profitability, SOPH's ROE is -1.41%, compared to CERN's ROE of +0.14%. Regarding short-term risk, SOPH is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CERN's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas CSLT's P/E ratio is -37.27. In terms of profitability, SOPH's ROE is -1.41%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, SOPH is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for SOPH.Check CSLT's competition here

SOPHiA GENETICS S.A. (NASDAQ: SOPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SOPH stands at 403.5M. In comparison, NH has a market cap of 0. Regarding current trading prices, SOPH is priced at $5.87 on the NASDAQ, while NH trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SOPH currently has a P/E ratio of -11.29, whereas NH's P/E ratio is -0.12. In terms of profitability, SOPH's ROE is -1.41%, compared to NH's ROE of +0.35%. Regarding short-term risk, SOPH is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for SOPH.Check NH's competition here